ATXIOTCPharmaceutical PreparationsFiscal year ends December 31
AVENUE THERAPEUTICS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$0.43+0.00 (0.00%)
Close on Oct 16, 2026
- Market cap
- $1.42M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$0.3100 (−41.89%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
AVENUE THERAPEUTICS, INC. reported revenue of $1.40M for fiscal 2025.
Revenue
$1.40M
FY2025
Operating income
-$2.90M
TTM Q2 2026
EPS, diluted
-$0.85
-160.7% vs. a year earlier
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $1.42M
- P/E ratio
- –
- Price to sales
- 1.01
- Price to book
- 2.49
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $1.40M
- Net income
- -$2.78M
- EPS, diluted
- -$0.85
- Book value per share
- $0.17
- Diluted shares
- 3M
Eleven years at a glance
Fiscal years 2015 to 2025 and trailing twelve months, USD
Revenue
–
Operating income
-$2.90M
Net income
-$2.78M
EPS, diluted
-$0.85-160.7% YoY
Reported periodTrailing twelve months